Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study.

[1]  P. Emery,et al.  A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial , 2019, Annals of the rheumatic diseases.

[2]  L. Coates,et al.  Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab , 2018, Rheumatology.

[3]  L. Coates,et al.  Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study , 2018, Arthritis Research & Therapy.

[4]  A. Gerards,et al.  Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis , 2018, Arthritis care & research.

[5]  M. D. de Wit,et al.  Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries , 2018, Annals of the rheumatic diseases.

[6]  A. Gottlieb,et al.  Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value , 2018, The Journal of Rheumatology.

[7]  L. Coates,et al.  What Should Be the Primary Target of “Treat to Target” in Psoriatic Arthritis? , 2018, The Journal of Rheumatology.

[8]  L. Coates,et al.  Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2‐Year Results From a Multicenter, Randomized, Double‐Blind, Parallel‐Group, Placebo‐Controlled Phase III Study , 2018, Arthritis care & research.

[9]  J. Smolen,et al.  Early response to therapy predicts 6-month and 1-year disease activity outcomes in psoriatic arthritis patients , 2018, Rheumatology.

[10]  J. Smolen,et al.  To DAPSA or not to DAPSA? That is not the question , 2018, Annals of the rheumatic diseases.

[11]  A. Gottlieb,et al.  4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis , 2018, RMD Open.

[12]  E. Soriano,et al.  Enthesitis: from pathophysiology to treatment , 2017, Nature Reviews Rheumatology.

[13]  L. Coates,et al.  Considerations for the definition of remission criteria in psoriatic arthritis. , 2017, Seminars in arthritis and rheumatism.

[14]  L. Coates,et al.  Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort , 2017, Annals of the rheumatic diseases.

[15]  A. Gottlieb,et al.  Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study , 2017, Rheumatology.

[16]  M. Dougados,et al.  Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force , 2017, Annals of the rheumatic diseases.

[17]  A. Deodhar,et al.  Minimal disease activity in axial spondyloarthritis: the need of the hour and a proposal for development , 2017, Current opinion in rheumatology.

[18]  C. Ospelt,et al.  Why location matters — site-specific factors in rheumatic diseases , 2017, Nature Reviews Rheumatology.

[19]  F. Perrotta,et al.  Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort , 2017, The Journal of Rheumatology.

[20]  J. Smolen,et al.  FRI0498 Outcomes associated with achievement of various treatment targets in patients with psoriatic arthritis receiving adalimumab , 2017 .

[21]  L. Coates,et al.  The Changing Face of Clinical Trials in Psoriatic Arthritis , 2017, Current Rheumatology Reports.

[22]  L. Coates,et al.  Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations , 2016, Nature Reviews Rheumatology.

[23]  B. Shea,et al.  International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials , 2016, Annals of the rheumatic diseases.

[24]  J. Smolen,et al.  Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression , 2016, Annals of the rheumatic diseases.

[25]  C. Lee,et al.  THU0440 Ixekizumab Provides Sustained Improvement up To 52 Weeks of Disease Activity as Assessed by Composite Measure Scores in Biologic Disease-Modifying Antirheumatic Drug (bDMARD)-Naive Patients with Active Psoriatic Arthritis , 2016 .

[26]  L. Coates,et al.  Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo‐Controlled Study , 2016, Arthritis care & research.

[27]  L. Coates,et al.  Treating to target in psoriatic arthritis: how to implement in clinical practice , 2015, Annals of the rheumatic diseases.

[28]  M Cutolo,et al.  European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update , 2015, Annals of the rheumatic diseases.

[29]  D. M. van der Heijde,et al.  Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. , 2015, The New England journal of medicine.

[30]  A. Gottlieb,et al.  Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial , 2015, The Lancet.

[31]  J. Smolen,et al.  Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for PSoriatic Arthritis (DAPSA). A brief review. , 2015, Clinical and experimental rheumatology.

[32]  J. Smolen,et al.  Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score , 2015, Annals of the rheumatic diseases.

[33]  L. Coates,et al.  Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial , 2014, The Lancet.

[34]  P. Mease,et al.  Application and Modifications of Minimal Disease Activity Measures for Patients with Psoriatic Arthritis Treated with Adalimumab: Subanalyses of ADEPT , 2013, The Journal of Rheumatology.

[35]  C. Salvarani,et al.  Clinical assessment in psoriatic arthritis. , 2011, Reumatismo.

[36]  L. Coates,et al.  Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data , 2010, Arthritis care & research.

[37]  L. Coates,et al.  Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment , 2009, Annals of the rheumatic diseases.

[38]  D. Gladman,et al.  Psoriatic arthritis: epidemiology, clinical features, course, and outcome , 2005, Annals of the rheumatic diseases.

[39]  A. Gottlieb,et al.  Psoriatic arthritis for the dermatologist. , 2015, Dermatologic clinics.